Spyre Therapeutics, Inc. - SYRE
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Oct 01, 2026 | SCHEDULE 13G | Paradigm BioCapital Advisors LP | 5.1% | 4,457,450 | View |
| Oct 01, 2026 | SCHEDULE 13G | Paradigm BioCapital Advisors GP LLC | 5.1% | 4,457,450 | View |
| Oct 01, 2026 | SCHEDULE 13G | Senai Asefaw, M.D. | 5.1% | 4,457,450 | View |
| Oct 01, 2026 | SCHEDULE 13G | Paradigm BioCapital International Fund Ltd. | 4.5% | 3,928,646 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 4.9% | 4,319,496 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Joseph Edelman | 4.9% | 4,319,496 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 4.9% | 4,319,496 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | RTW Investments, LP | 4.8% | 4,251,996 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Roderick Wong | 4.8% | 4,251,996 | View |
| Jun 23, 2026 | SCHEDULE 13D/A | — | 9.99% | — | View |
| Apr 22, 2026 | SCHEDULE 13G | Perceptive Advisors LLC | 5.0% | 4,319,496 | View |
| Apr 22, 2026 | SCHEDULE 13G | Joseph Edelman | 5.0% | 4,319,496 | View |
| Apr 22, 2026 | SCHEDULE 13G | Perceptive Life Sciences Master Fund, Ltd. | 5.0% | 4,319,496 | View |
| Apr 20, 2026 | SCHEDULE 13D/A | — | 9.99% | — | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.